REal-world Data of CARdiometabolic ProtEcTion

NCT07038083 | Recruiting DMC

• 1 other identifier: RED-CARPET Study
• Study Type: observational
• Target: 40,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-center, historical prospective cohort study including patients diagnosed with metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia. The primary outcome of the study is all-cause death and cardiovascular death, and the secondary outcome is major adverse cardiovascular events. We aim to measure associations of established or suspected cardiometabolic disease (CMD) risk factors and cardiovascular disease outcomes in a real-world representative cohort.

Conditions

Cardiometabolic Diseases

Keywords

Cardiometabolic Diseases; all-cause mortality; Cardiovascular death; Major adverse cardiovascular events

Outcome Measures

Primary Outcomes (2)

• all-cause mortality

  Death due to any cause after enrollment

  Through study completion, an average of 5 years

• Cardiovascular death

  Death caused by cardiac causes

  Through study completion, an average of 5 years

Secondary Outcomes (1)

• Major adverse cardiovascular events

  Through study completion, an average of 5 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients diagnosed with cardiometabolic diseases during hospitalization were enrolled.

You may qualify if:

• Patients over 18 years old;
• Patients with clinical diagnosis of metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia.
• Hypertension and normal high blood pressure: Three standardized blood pressure measurements in the clinic on different days, and all the blood pressure values of the three measurements were systolic blood pressure ≥ 120 mmHg and/or diastolic blood pressure ≥ 80 mmHg;
• Diabetes: ① Typical symptoms of diabetes, and any of the following: ② Random blood glucose ≥ 11.1 mmol/L; ③ Fasting blood glucose (FPG) ≥ 7.0 mmol/L; ④ OGTT 2-hour postprandial blood glucose ≥ 11.1 mmol/L; ⑤ HbA1c ≥ 6.5%;
• Obesity and overweight: Body mass index (BMI) ≥ 24 kg/m²;
• Dyslipidemia: At least one of the following lipid indicators is abnormal: ① Total cholesterol (TC) ≥ 6.2 mmol/L; ② Low-density lipoprotein cholesterol (LDL-C) ≥ 4.1 mmol/L; ③ High-density lipoprotein cholesterol (HDL-C) \< 1.0 mmol/L; ④ Triglyceride (TG) ≥ 2.3 mmol/L; ⑤ Lipoprotein(a) ≥ 30 mg/dL;
• Hyperuricemia: The fasting blood uric acid levels on two different days were \> 420 μmol/L (7 mg/dL) in men and \> 360 μmol/L (6 mg/dL) in women.

You may not qualify if:

• Patients unable to provide informed consent.

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

The First Affiliated Hospital of Sun Yat-sen Univerity

Guangzhou, Guangdong, 510000, China

RECRUITING

Central Study Contacts

Xiaodong Zhuang

CONTACT

+8613760755035; zhuangxd3@mail.sysu.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 15 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 18, 2025
• First Posted: June 26, 2025
• Study Start: January 1, 2014
• Primary Completion (Estimated): January 1, 2044
• Study Completion (Estimated): January 1, 2044
• Last Updated: June 26, 2025

Record last verified: 2025-06

Locations

CN (1)